Research programme: VLA-4 antagonists - Biogen Idec

Drug Profile

Research programme: VLA-4 antagonists - Biogen Idec

Alternative Names: VLA-4 antagonists research programme - Biogen Idec

Latest Information Update: 04 Mar 2009

Price : $50

At a glance

  • Originator Biogen Idec
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Multiple sclerosis

Most Recent Events

  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 10 Jul 2002 This programme is still in active development
  • 12 Oct 1999 Preclinical development for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top